

## Lao PDR

### Support for Vaccine: Pentavalent This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b>	Lao PDR						
<b>2. Vaccine grant number:</b>	1215-LAO-04A-X, 16-LAO-04a-X, 17-LAO-04a-X, 1820-LAO-04a-X						
<b>3. Date of Decision Letter:</b>	7-Jun-19						
<b>4. Date of the Partnership Framework Agreement:</b>	7-Jun-13						
<b>5. Programme title:</b>	New Vaccine Support (NVS), Pentavalent, Routine						
<b>6. Vaccine type:</b>	Pentavalent						
<b>7. Requested product presentation and formulation of vaccine:</b>	DTP-HepB-Hib, 1 dose(s) per vial, LIQUID						
<b>8. Programme Duration:<sup>1</sup></b>	2009-2020						
<b>9. Programme Budget (indicative):<sup>2</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2009-2018	2019	2020	2021	2022	2023	Total <sup>2</sup>
Programme Budget (US\$)	9,837,293	216,000	228,000	-	-	-	10,281,293
<b>10. Vaccine introduction grant</b>	Not applicable						
<b>11. Product switch grant</b>	Not applicable						
<b>12. Indicative Annual Amounts:<sup>3</sup></b>	(subject to the terms of the Partnership Framework Agreement, if applicable)						
<b>Type of supplies to be purchased with Gavi funds</b>	<b>2009-2018</b>	<b>2019</b>					<b>2020</b>
Number of vaccine doses		192,700					-
Annual Amounts (US\$)	9,837,293	216,000					-
<b>13. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						
<b>14. Self-procurement:</b>	Not applicable						
<b>15. Co-financing obligations:</b>	<p>According to the co-financing policy, the Country falls within the group: <span style="float: right;">Accelerated transition phase</span></p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>						

<sup>1</sup>This is the entire duration of the Programme.

<sup>2</sup>This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup>This is the total amount approved by Gavi.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021	2022	2023
Number of vaccine doses	162,600	310,500	-	-	-
Number of AD syringes	166,700	325,300	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	1,850	3,600	-	-	-
Value of vaccine doses (US\$)	170,662	326,006	-	-	-
Total co-financing payments (US\$) (including freight)	190,000	363,000	-	-	-

**16. Operational support for catch-up campaigns:**

Not applicable

**17. Additional Reporting Requirements:**

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>Vaccine stock levels including buffer stock, by end of March;</li> <li>Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.</li> <li>Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

**18. Financial clarifications:**

Not applicable

**19. Other conditions:**

Not applicable

Signed by,

**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

7 June 2019